Evidence map›Paper›PMID 30137618›Full record

ReviewNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2019

Alpha7 Nicotinic Receptors as Therapeutic Targets in Schizophrenia.

Jason R Tregellas, Korey P Wylie

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Selective 5HT3 antagonists and sensory processing: a systematic review.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Hidden complexity of α7 nicotinic acetylcholine receptor desensitization revealed by MD simulations and Markov state modeling.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jason R TregellasDepartment of Psychiatry, University of Colorado School of Medicine, Aurora, CO.
Korey P WylieDepartment of Psychiatry, University of Colorado School of Medicine, Aurora, CO.

Funding

Neuronal Effects of Exercise on SchizophreniaR01MH102224 · NIMH · UNIVERSITY OF COLORADO DENVER · PI TREGELLAS, JASON R · 2014 to 2018
$1.9M
Nicotinic Agonist Effects on BMI and Neuronal Response in Overweight/Obese AdultsR01DK103691 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI TREGELLAS, JASON R · 2015 to 2019
$1.9M
fMRI of Cholinergic Mechanisms in SchizophreniaI01CX000459 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI TREGELLAS, JASON R · 2011 to 2015
–
CSRD VA I01 CX000459NIDDK NIH HHS R01 DK103691NIMH NIH HHS R01 MH102224
6 · The paper itself

Abstract

While current treatments for schizophrenia often provide much relief for positive symptoms such as hallucinations, other symptoms, particularly cognitive deficits, persist and contribute to substantial suffering and reduced quality of life for patients. In searching for novel therapeutic avenues to treat cognitive deficits in schizophrenia, recent work is exploring nicotinic receptor neurobiology. Supported by a large body of evidence, with contributions from studies of smoking behaviors, genetics, receptor distribution and function, animal models and nicotinic effects on illness symptoms, the alpha7 nicotinic receptor has emerged as a potential therapeutic target. Despite promise in early clinical trials, however, no drug targeting nicotinic systems has succeeded in larger phase 3 trials. Following a brief review of nicotinic receptor biology and the evidence that has led to pursuit of alpha7 nicotinic agonism as a therapeutic strategy, this review will provide an update on the status of recent trials, discuss potential issues that may have contributed to negative outcomes, and point to new directions and promising advances in developing alpha7 nicotinic receptor-based treatment for cognitive symptoms in schizophrenia. IMPLICATIONS: By examining alpha7 nicotinic receptor biology and recent efforts to target the receptor in clinical trials, it is hoped that investigators will be motivated to explore novel, promising directions focusing on the receptor as a strategy to treat cognitive symptoms in schizophrenia.

Indexed as

Molecular Targeted Therapyalpha7 Nicotinic Acetylcholine ReceptorAnimalsHumansNicotinic AgonistsSchizophreniaalpha7 Nicotinic Acetylcholine ReceptorNicotinic Agonists

Identifiers

PMID30137618
PMCPMC6379034

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.